Robin Shah, Co-Founder and Chief Executive Officer; Dr. Bobby Green, Co-Founder, Chief Medical Officer, and President; and Dr. Brad Diephuis, President and Chief Operating Officer
What You Should Know:
– Thyme Care, a value-based cancer care…
Continue Reading
What You Should Know:
– Daymark Health, a company dedicated to redefining the cancer care experience secures $20M in Series A funding round led by Healthier Capital and Blue Venture Fund, with continued participation from…
Continue Reading
This systematic review examines the cost-effectiveness, utility, and budget impact of clinical artificial intelligence (AI) interventions across diverse healthcare settings. Nineteen studies spanning oncology, cardiology, ophthalmology, and infectious diseases demonstrate that AI improves diagnostic…
Continue Reading
What You Should Know:
– Method AI, a medical technology company focused on improving oncology outcomes secures $20M in Series A funding led by a private family office, with participation from Cleveland Clinic and JobsOhio…
Continue Reading
Prostate cancer (PCa) ranks among the most prevalent cancers in men worldwide. Biochemical recurrence (BCR) presents a major clinical challenge in PCa management, with significant prognostic heterogeneity observed among patients post-recurrence. This study aimed…
Continue Reading
What You Should Know:
– Ryght AI, a leading AI clinical trial developer, today announced a partnership with Biorasi, a global clinical research organization (CRO) specializing in dermatology, oncology, neurology, and nephrology studies.
– The collaboration will bring advanced,…
Continue Reading
What You Should Know:
– Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, announced today that the U.S. Food and Drug Administration (FDA) has granted De Novo authorization for ArteraAI…
Continue Reading
In (immune)oncology, virtual twins (VTs) offer patient-individual decision support. Nevertheless, current VTs do not incorporate the unique properties of engineered adoptive cellular immunotherapies (eACIs). Here, we outline the minimal design specifications for VTs for…
Continue Reading
This review summarizes the current literature on the use of wearable devices for collecting physiological data in pediatric and young adult (0−25 years) oncology. Searches were conducted in MEDLINE, PubMed and Embase, focusing on pediatric…
Continue Reading
What You Should Know:
– Flatiron Health, a leading healthtech company dedicated to improving cancer care and advancing research using real-world data (RWD), today announced that its international oncology research network has tripled in size…
Continue Reading
